Among the most interesting parts of the CC was S.

Among the most interesting parts of the CC was S. Kelly's statement that they were in talks with someone, who wanted to use LL for their own purposes and pay for it. I don't want to raise unreasonable expectations here, but this has been on my mind ever since, what could it be? A large hospital chain, a company operating in several countries, that treats patients, who are particularly at risk from Covid, another pharmaceutical company that wants to trial LL to accompany its own product?

WUM